Abstract
Human ankyrin repeat and suppressor of cytokine signaling box protein 9 (hASB9), a subunit of an Elongin Ccullin- SOCS box (ECS) E3 ubiquitin ligase complex, is believed to be involved in specific substrate-recognition for ubiquitination and degradation. In fact, this specific substrate-recognition is determined by the ankyrin repeats of hASB9 protein. Here, we have cloned and overexpressed the hASB9-2, the splice variant of hASB9 with only one ankyrin repeat domain, as a 6His-tagged recombinant protein in Escherichia coli. The purified hASB9-2 protein was crystallized by the hanging-drop vapor-diffusion technique and diffracted to 2.2Å resolution. The data showed that the cubic hASB9-2 crystal belongs to space group P4332 with unit-cell parameters (a=b=c=129.25Å, α=β=γ=90°). An asymmetric unit in the crystal was assumed to contain one protein molecule giving the Matthews Coefficient factor of 2.81 and the solvent content of 56.3%.
Keywords: hASB9, hASB9-2, ankyrin repeat, crystallization, preliminary X-ray analysis
Protein & Peptide Letters
Title: Crystallization and Preliminary X-Ray Analysis of the Splice Variant of Human Ankyrin Repeat and Suppressor of Cytokine Signaling Box Protein 9 (hASB9-2)
Volume: 16 Issue: 3
Author(s): Xiangwei Fei, Yong Zhang, Xing Gu, Rui Qiu, Yumin Mao and Chaoneng Ji
Affiliation:
Keywords: hASB9, hASB9-2, ankyrin repeat, crystallization, preliminary X-ray analysis
Abstract: Human ankyrin repeat and suppressor of cytokine signaling box protein 9 (hASB9), a subunit of an Elongin Ccullin- SOCS box (ECS) E3 ubiquitin ligase complex, is believed to be involved in specific substrate-recognition for ubiquitination and degradation. In fact, this specific substrate-recognition is determined by the ankyrin repeats of hASB9 protein. Here, we have cloned and overexpressed the hASB9-2, the splice variant of hASB9 with only one ankyrin repeat domain, as a 6His-tagged recombinant protein in Escherichia coli. The purified hASB9-2 protein was crystallized by the hanging-drop vapor-diffusion technique and diffracted to 2.2Å resolution. The data showed that the cubic hASB9-2 crystal belongs to space group P4332 with unit-cell parameters (a=b=c=129.25Å, α=β=γ=90°). An asymmetric unit in the crystal was assumed to contain one protein molecule giving the Matthews Coefficient factor of 2.81 and the solvent content of 56.3%.
Export Options
About this article
Cite this article as:
Fei Xiangwei, Zhang Yong, Gu Xing, Qiu Rui, Mao Yumin and Ji Chaoneng, Crystallization and Preliminary X-Ray Analysis of the Splice Variant of Human Ankyrin Repeat and Suppressor of Cytokine Signaling Box Protein 9 (hASB9-2), Protein & Peptide Letters 2009; 16 (3) . https://dx.doi.org/10.2174/092986609787601688
DOI https://dx.doi.org/10.2174/092986609787601688 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Synthetic Strategies for Monocyclic Azole Nucleus and Its Role in Drug Discovery and Development
Current Organic Synthesis Ultrasound Contrast Agents: Updated Data on Safety Profile
Current Pharmaceutical Design Tuberculosis Infection Under Anti-TNF Alpha Treatment
Current Drug Safety Telomere End Protection in Stem Cells and Cancer Cells
Current Cancer Therapy Reviews Diet and miRNA: Epigenetic Regulator or a New Class of Supplements?
MicroRNA The Effects of Vitamin Therapy on ASD and ADHD: A Narrative Review
CNS & Neurological Disorders - Drug Targets Ribosome Inactivating Proteins (RIPs) from Momordica charantia for Anti Viral Therapy
Current Molecular Medicine Platelet-Derived Chemokines in Atherogenesis: What’s New?
Current Vascular Pharmacology Non-Lipid Effects of Statins: Emerging New Indications
Current Vascular Pharmacology The Evil Axis of Obesity, Inflammation and Type-2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Increased Neuronal Injury in Transgenic Mice with Neuronal Overexpression of Human Cyclooxygenase-2 is reversed by Hypothermia and Rofecoxib Treatment
Current Neurovascular Research Editorial(Hot Topic: Proteolysis in Health and Disease)
Current Pharmaceutical Design Preface [Hot topic: Potential Therapeutic Agents for Parkinsons Disease (Executive Editor: Masato Asanuma)]
Current Pharmaceutical Design Pharmacological Therapies for Pediatric and Neonatal ALI/ARDS: An Evidence-Based Review
Current Drug Targets “Forbidden” Disulfides: Their Role as Redox Switches
Current Protein & Peptide Science Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling
Current Pharmaceutical Design Editorial [Hot Topic: Oxidative Balance: Experimental and Clinical Perspectives (Executive Editor: Fortunato Vesce)]
Current Pharmaceutical Design Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design BRAda: A Robust Method for Identification of Pre-microRNAs by Combining Adaboost Framework with BP and RF
Letters in Organic Chemistry New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs
Current Medicinal Chemistry